- Policy
- 'Cabometyx' for ncRCC, failed to nego for expanded reimb
- by Lee, Tak-Sun May 28, 2025 05:57am
- The anticancer drug Cabometyx tab (cabozantinib, Ipsen Korea), a treatment of kidney cancer, did not pass the expanded reimbursement during negotiations with the National Health Insurance Service (NHIS). Cabometyx tab gatherered attention following reimbursement for the first-line treatment of patients with non-clear renal cell carcinoma
- Policy
- Expanded reimb for Jardiance's CKD indication imminent
- by Lee, Tak-Sun May 27, 2025 06:19am
- It is to be watched whether the SGLT-2 inhibitor Jardiance (empagliflozin, Boehringer Ingelheim) will be approved for expanded reimbursement to include chronic kidney disease (CKD) indication, in addition to diabetes and chronic heart failure indications. The evaluation by the Health Insurance Review & Assessment Service (HIRA) is expecte
- Policy
- Rinvoq reimbursed for active progressive psoriatic arthritis
- by Whang, byung-woo May 27, 2025 06:18am
- AbbVie Korea's Rinvoq has become the first oral JAK inhibitor to be covered by insurance for psoriatic arthritis in Korea. On the 26th, AbbVie Korea announced that Rinvoq (upadacitinib), a once-daily oral treatment and selective JAK inhibitor, will be reimbursed for the treatment of active and progressive psoriatic arthritis in adults
- Policy
- Moderate-risk trial granted for 'Amtagvi' for melanoma
- by Lee, Jeong-Hwan May 26, 2025 05:56am
- The government has approved a moderate-risk clinical study to treat refractory melanoma patients using the T-cell therapy, Amtagvi. The government also approved a high-risk clinical study that administer multi-virus antigen-specific immune T-cells to pediatric and adolescent patients with resistant·refractory multi-virus infections who un
- Policy
- Amgen’s SCLC drug tarlatamab soon to be approved in KOR
- by Lee, Hye-Kyung May 26, 2025 05:55am
- The approval of Amgen's new drug for small cell lung cancer, tarlatamab (U.S. brand name Imdelltra), is imminent in Korea. According to industry sources on the 23rd, the Ministry of Food and Drug Safety has completed its safety and efficacy review for tarlatamab. The MFDS's completion of the review means a new drug approval will follow
- Policy
- Myung In’s Nuvigil first generic listed for reimb in Korea
- by Lee, Tak-Sun May 23, 2025 05:52am
- Myung In Pharm’s first generic version of the narcolepsy drug Nuvigil (amodapine) is expected to be sold in earnest following its reimbursement listing in June. Currently, narcolepsy treatments are primarily composed of two ingredients: modafinil and amodafinil. With Mitsubishi Tanabe Pharma's ' 'Wakix (pitolisant)' recently withdrawi
- Policy
- Govt-ind sees consensus on 'AI-based new drug governance'
- by Lee, Jeong-Hwan May 22, 2025 06:09am
- The current administration has promised support and promotion for the establishment of a national governance system for AI-based new drugs, which the domestic pharmaceutical industry has called for the attention of the presidential election candidates. The National Bio Committee, which reports directly to the president, has selected AI-
- Policy
- 'AI-enabled stem cell for pediatric epilepsy proves effect'
- by Lee, Hye-Kyung May 21, 2025 06:36am
- A new treatment possibility has opened up for pediatric epilepsy patients who have shown little response to existing treatments. The Korea Health Industry Development Institute (President: Soondo Cha) announced on the 19th that Professor Hoon-Chul Kang’s research team at Yonsei University Severance Children's Hospital has successfully disco
- Policy
- Citus generics price raised, Ameliebou Inj huge price cut
- by Lee, Tak-Sun May 20, 2025 06:00am
- Prices of Citus generic drugs will be raised. As the price of original Citus has been adjusted, the prices of generic drugs that were reimbursement-listed in January have been recalculated. Meanwhile, the price of Samsung Bioepis' Lucentis biosimilar 'Ameliebou Inj' has been substantially cut, resulting in a significant difference from the or
- Policy
- MFDS to review reference drug application every 2 months
- by Lee, Hye-Kyung May 20, 2025 05:59am
- The change in the procedure for selecting reference drugs for pharmaceutical equivalence tests is being well received by the domestic pharmaceutical industry. The Ministry of Food and Drug Safety recently announced a revision to the 'Guideline for Selecting Reference drugs for Pharmaceutical Equivalence Tests' and is seeking opinions on the c
